Longlasting remissions after treatment with rituximab for autoimmune myositis.
Eugen
E
Feist
Thomas
T
Dörner
Helmut
H
Sörensen
Gerd-R
GR
Burmester
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D003882:Dermatomyositis / Q000188:drug therapy*; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D010257:Paraneoplastic Syndromes / Q000188:drug therapy*; D000069283:Rituximab; D013995:Time; D017211:Treatment Failure
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab